SCHEMBL6239541

SCHEMBL6239541

Cc1cccc(Oc2ccc3c(c2)CC(Br)C3=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.46
HTT P42858 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
ALDH1A1 P00352 4/20 0.44
LYN P07948 1/20 0.40
METAP1 P53582 3/20 0.39
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
GRIA2 P42262 2/20 0.38
EZH2 Q15910 1/20 0.37
AR P10275 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6972986 0.79 METAP1 (0.54) METAP1MAOAMAOBACHE
SCHEMBL6205730 0.79 MAOA (0.48) POLBALDH1A1METAP1MAPK1MEN1
SCHEMBL4462617 0.78 METAP1 (0.58) ALDH1A1METAP1KDM4EACHE
SCHEMBL6237556 0.74 TDP1 (0.50) TDP1HTTL3MBTL1POLBMAPT
SCHEMBL6205297 0.71 CES1 (0.47) METAP1KDM4E
SCHEMBL9136817 0.71 METAP1 (0.42) ALDH1A1METAP1ACHE
Dimethylformamide SCHEMBL7845290 0.70 METAP1 (0.52) METAP1MAOAMAOBACHE
SCHEMBL14159539 0.70 ALDH1A1 (0.80) TDP1HTTL3MBTL1MAPTALDH1A1
SCHEMBL10013917 0.70 ALDH1A1 (0.80) TDP1HTTL3MBTL1MAPTALDH1A1
SCHEMBL29746015 0.70 ALDH1A1 (0.72) TDP1HTTL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157015-B1 USE OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LIPOMETABOLIC DISORDERS, OBESITAS AND TYP II DIABETES AVENTIS PHARMA GMBH (DE) 2005-05-11 EP disclosed
EP-1173176-B1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA GMBH (DE) 2004-05-26 EP disclosed
US-6476059-B1 Use of polycyclic 2-aminothiazole systems for the treatment of obesity AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-11-05 US disclosed
EP-1173176-A1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY Aventis Pharma Deutschland GmbH (DE) 2002-01-23 EP disclosed
EP-1157015-A1 POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS Aventis Pharma Deutschland GmbH (DE) 2001-11-28 EP disclosed
US-6251922-B1 TREATMENT OF OBESITY AND DIABETES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-06-26 US disclosed
WO-2000051602-A1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
WO-2000051995-A1 POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed